Home › Funds › Enavate Sciences GP, LLC › BBOT
Enavate Sciences GP, LLC position in BBOT
BridgeBio Oncology Therapeutic Inc · Health Care
Enavate Sciences GP, LLC reported holding 2,626,946 shares of BBOT (BridgeBio Oncology Therapeutic Inc) in its Q2 2026 13F filing — a position valued at US$20.0M, representing 5.80% of its reported portfolio and ranking #4 among its reported holdings. Enavate Sciences GP, LLC has disclosed BBOT holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Enavate Sciences GP, LLC's BBOT position evolved
Enavate Sciences GP, LLC first disclosed a stake in BBOT in Q3 2025 at 2,626,946 shares (US$30.4M). The position peaked in Q4 2025 at 2,626,946 shares, worth US$32.9M. Across 4 filings, Enavate Sciences GP, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 2,626,946 shares valued at US$20.0M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 2.63M | $30.42M | New |
| Q4 2025 | 2.63M | $32.89M | Hold |
| Q1 2026 | 2.63M | $23.51M | Hold |
| Q2 2026 | 2.63M | $20.02M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BBOT and 13F data
BBOT (BridgeBio Oncology Therapeutic Inc) is a Health Care company. 74 other funds we track also report a position in BBOT — the largest reported positions include Cormorant Asset Management, LP (US$136.2M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$37.2M), Omega Fund Management, LLC (US$25.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BBOT
- Cormorant Asset Management, LP 17.88M sh · $136.23M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.89M sh · $37.23M · Q2 2026
- Omega Fund Management, LLC 3.29M sh · $25.07M · Q2 2026
- Alphabet Inc. 2.82M sh · $21.51M · Q2 2026
- EcoR1 Capital, LLC 2.82M sh · $21.51M · Q2 2026
- Novo Holdings A/S 2.25M sh · $17.14M · Q2 2026
- Laurion Capital Management LP 2.00M sh · $15.26M · Q2 2026
- Aisling Capital Management LP 1.02M sh · $7.76M · Q2 2026
- Opaleye Management Inc. 700.00K sh · $5.33M · Q2 2026
- Catalio Capital Management, LP 318.41K sh · $2.43M · Q2 2026
- Casdin Capital 282.31K sh · $2.15M · Q2 2026
- Avidity Partners Management LP 43.85K sh · $334.16K · Q2 2026
More on Enavate Sciences GP, LLC
FAQ
How long has Enavate Sciences GP, LLC held BBOT?
Enavate Sciences GP, LLC has disclosed BBOT holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Enavate Sciences GP, LLC's current position in BBOT?
As of Q2 2026, Enavate Sciences GP, LLC holds 2.63M shares of BBOT (BridgeBio Oncology Therapeutic Inc), valued at $20.02M, representing 5.80% of its reported portfolio and ranking #4.
Has Enavate Sciences GP, LLC been buying or selling BBOT?
In the latest 13F filing (Q2 2026), Enavate Sciences GP, LLC held unchanged its position in BBOT. The position peaked in Q4 2025 at 2.63M shares.
Which other funds hold BBOT?
Other major institutional holders of BBOT include Cormorant Asset Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Omega Fund Management, LLC, among 74 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.